Insmed (INSM) Stock Forecast & Price Target

Compare

933 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSM Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$142.29

▲(15.81% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $142.29 with a high forecast of $240.00 and a low forecast of $101.00. The average price target represents a 15.81% change from the last price of $122.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","154":"$154","241":"$241","110.5":"$110.5","197.5":"$197.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$142.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$101.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,110.5,154,197.5,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.69,118.79076923076923,128.89153846153846,138.9923076923077,149.09307692307692,159.19384615384615,169.29461538461538,179.39538461538461,189.49615384615385,199.59692307692308,209.6976923076923,219.79846153846154,229.89923076923077,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.69,111.27461538461539,113.85923076923076,116.44384615384615,119.02846153846153,121.61307692307692,124.19769230769231,126.78230769230768,129.36692307692306,131.95153846153846,134.53615384615384,137.1207692307692,139.70538461538462,{"y":142.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.69,108.09846153846154,107.50692307692307,106.91538461538461,106.32384615384615,105.73230769230769,105.14076923076922,104.54923076923077,103.95769230769231,103.36615384615385,102.77461538461539,102.18307692307692,101.59153846153846,{"y":101,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$240.00

Average Price Target$142.29

Lowest Price Target$101.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andy Chen

Wolfe Research

$109→$173

Buy

40.80%

Upside

Reiterated

08/14/25

Wolfe Research Sticks to Their Buy Rating for Insmed (INSM)Wolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $173.00 (from $109.00) while maintaining a Outperform rating.

Stephen Willey

Stifel Nicolaus

$121→$145

Buy

18.01%

Upside

Reiterated

08/14/25

Stifel Nicolaus Reaffirms Their Buy Rating on Insmed (INSM)

Owen Dosehart

TR | OpenAI - 4o

$118→$121

Hold

-1.52%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Srikripa Devarakonda

Truist Financial

$126→$139

Buy

13.13%

Upside

Reiterated

08/14/25

Truist Financial Sticks to Its Buy Rating for Insmed (INSM)

Ritu Baral

TD Cowen

$135→$154

Buy

25.34%

Upside

Reiterated

08/13/25

Insmed's Brensocatib Approval Boosts Market Potential and Stock Valuation

Andrew Fein

H.C. Wainwright

$120→$240

Buy

95.33%

Upside

Reiterated

08/13/25

H.C. Wainwright Remains a Buy on Insmed (INSM)

Trung Huynh

UBS

$133→$140

Buy

13.94%

Upside

Reiterated

08/13/25

Insmed (INSM) Receives a Buy from UBS

Jason Zemansky

Bank of America Securities

$121→$142

Buy

15.57%

Upside

Reiterated

08/13/25

Brinsupri approval sets stage for next leg of Insmed growth, says BofABrinsupri approval sets stage for next leg of Insmed growth, says BofA

Tiago Fauth

Wells Fargo

$130→$140

Buy

13.94%

Upside

Reiterated

08/13/25

Insmed's BRINSUPRI Approval and Strategic Pricing Justify Buy Rating and Increased Price Target

Maxwell Skor

Morgan Stanley

$112→$126

Hold

2.55%

Upside

Downgraded

08/13/25

Insmed downgraded to Equal Weight from Overweight at Morgan StanleyInsmed downgraded to Equal Weight from Overweight at Morgan Stanley

Elvira Scotto

RBC Capital

$120→$138

Buy

12.31%

Upside

Reiterated

08/12/25

Insmed price target raised to $138 from $120 at RBC CapitalInsmed price target raised to $138 from $120 at RBC Capital

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

08/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (NASDAQ: PROK), Oric Pharmaceuticals (NASDAQ: ORIC) and Insmed (NASDAQ: INSM)

Kelly Shi

Jefferies

$129→$148

Buy

20.45%

Upside

Reiterated

08/12/25

Jefferies Remains a Buy on Insmed (INSM)Jefferies analyst Kelly Shi raised the price target on Insmed (NASDAQ: INSM) to $148.00 (from $129.00) while maintaining a Buy rating.

Graig Suvannavejh

Mizuho Securities

$130→$165

Buy

34.29%

Upside

Reiterated

08/12/25

Mizuho Securities Sticks to Their Buy Rating for Insmed (INSM)Bigger picture, having recently raised our 12‐month PT on INSM to $130 (implies ~20% upside), we reiterate our Outperform rating.

Joseph Schwartz

Leerink Partners

$115→$125

Buy

1.73%

Upside

Assigned

08/11/25

Leerink Partners Issues a Buy Rating on Insmed (INSM)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andy Chen

Wolfe Research

$109→$173

Buy

40.80%

Upside

Reiterated

08/14/25

Stephen Willey

Stifel Nicolaus

$121→$145

Buy

18.01%

Upside

Reiterated

08/14/25

Stifel Nicolaus Reaffirms Their Buy Rating on Insmed (INSM)

Owen Dosehart

TR | OpenAI - 4o

$118→$121

Hold

-1.52%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Srikripa Devarakonda

Truist Financial

$126→$139

Buy

13.13%

Upside

Reiterated

08/14/25

Truist Financial Sticks to Its Buy Rating for Insmed (INSM)

Ritu Baral

TD Cowen

$135→$154

Buy

25.34%

Upside

Reiterated

08/13/25

Insmed's Brensocatib Approval Boosts Market Potential and Stock Valuation

Andrew Fein

H.C. Wainwright

$120→$240

Buy

95.33%

Upside

Reiterated

08/13/25

H.C. Wainwright Remains a Buy on Insmed (INSM)

Trung Huynh

UBS

$133→$140

Buy

13.94%

Upside

Reiterated

08/13/25

Insmed (INSM) Receives a Buy from UBS

Jason Zemansky

Bank of America Securities

$121→$142

Buy

15.57%

Upside

Reiterated

08/13/25

Brinsupri approval sets stage for next leg of Insmed growth, says BofABrinsupri approval sets stage for next leg of Insmed growth, says BofA

Tiago Fauth

Wells Fargo

$130→$140

Buy

13.94%

Upside

Reiterated

08/13/25

Insmed's BRINSUPRI Approval and Strategic Pricing Justify Buy Rating and Increased Price Target

Maxwell Skor

Morgan Stanley

$112→$126

Hold

2.55%

Upside

Downgraded

08/13/25

Insmed downgraded to Equal Weight from Overweight at Morgan StanleyInsmed downgraded to Equal Weight from Overweight at Morgan Stanley

Elvira Scotto

RBC Capital

$120→$138

Buy

12.31%

Upside

Reiterated

08/12/25

Insmed price target raised to $138 from $120 at RBC CapitalInsmed price target raised to $138 from $120 at RBC Capital

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

08/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (NASDAQ: PROK), Oric Pharmaceuticals (NASDAQ: ORIC) and Insmed (NASDAQ: INSM)

Kelly Shi

Jefferies

$129→$148

Buy

20.45%

Upside

Reiterated

08/12/25

Jefferies Remains a Buy on Insmed (INSM)Jefferies analyst Kelly Shi raised the price target on Insmed (NASDAQ: INSM) to $148.00 (from $129.00) while maintaining a Buy rating.

Graig Suvannavejh

Mizuho Securities

$130→$165

Buy

34.29%

Upside

Reiterated

08/12/25

Mizuho Securities Sticks to Their Buy Rating for Insmed (INSM)Bigger picture, having recently raised our 12‐month PT on INSM to $130 (implies ~20% upside), we reiterate our Outperform rating.

Joseph Schwartz

Leerink Partners

$115→$125

Buy

1.73%

Upside

Assigned

08/11/25

Leerink Partners Issues a Buy Rating on Insmed (INSM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+12.00%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +12.00% per trade.

3 Months

xxx

Success Rate

18/22 ratings generated profit

Average Return

+34.02%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +34.02% per trade.

1 Year

Jason ZemanskyBank of America Securities

Success Rate

22/22 ratings generated profit

Average Return

+91.42%

reiterated a buy rating 2 days ago

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +91.42% per trade.

2 Years

xxx

Success Rate

22/22 ratings generated profit

Average Return

+180.99%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +180.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSM has received 42 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 142.29.

Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$1.36 with a range of -$1.67 to -$1.11. The previous quarter’s EPS was -$1.70. INSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year INSM has Preformed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $114.72M with a range of $104.80M to $121.97M. The previous quarter’s sales results were $107.42M. INSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.71% of the time in the same period. In the last calendar year INSM has Outperformed its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 142.29.

What is INSM’s upside potential, based on the analysts’ average price target?

Insmed has 15.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSM a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is Insmed’s price target?

The average price target for Insmed is 142.29. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $240.00 ,the lowest forecast is $101.00. The average price target represents 15.81% Increase from the current price of $122.87.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of INSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Insmed (INSM) Stock Forecast & Price Target

INSM Analyst Ratings

INSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

INSM Analyst Recommendation Trends

INSM Financial Forecast

INSM Earnings Forecast

INSM Sales Forecast

INSM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts